Trait absorption association with ketamine’s benefits and drug-context interactions in treatment-resistant depression: exploratory results from the MUSIK randomized clinical trial

Ketamine exerts rapid antidepressant effects in treatment-resistant depression (TRD) but therapeutic predictors remain elusive. The personality trait absorption – tendencies for immersive sensory, imaginative, and emotional experiences – influences responses to serotonergic psychedelics, like psilocybin, but has not been studied for ketamine. This study explores trait absorption’s influences on ketamine-therapy for TRD, including interactions with music- versus mindfulness-based support. This exploratory analysis draws on the MUSIK trial (NCT04701866), a multi-site, parallel, single-blind RCT at two Montreal hospitals, whose primary outcome examined hemodynamic effects of pairing ketamine with music. Thirty-two adults (aged 18-75 years) with severe TRD, receiving a structured psychedelic ketamine-therapy intervention, were randomized 1:1 to receive either music (n = 15) or matched non-music support (n = 17) during their six infusions (0.5 mg/kg over 40 min) over four weeks. Outcome assessors but not participants were blinded. Across 181 infusions, this exploratory outcome examined associations between baseline absorption and (1) changes in depression, anxiety, and suicidality; and (2) mystical/emotional experiences using linear correlations and multilevel models. Baseline trait absorption is associated (p ≤ .002) with pre-post improvements in depression (r = .721), anxiety (r = .546), and mean/peak Mystical Experience Questionnaire scores (r = .528-.637). In multilevel models, higher absorption is associated with steeper declines in depression and suicidality. Three-way interactions with timepoint and group suggest that music, versus matched non-music support, is associated with greater depression improvements in higher-absorption individuals (p <.001). Although confirmation in larger studies is required, this exploratory study suggests that trait absorption relates to ketamine’s benefits for TRD. Observed drug-context interactions highlight possible strategies for individuallytailoring ketamine-therapy. Low-dose ketamine can be very beneficial for severe depression even when other treatments have not helped. However, much remains unknown about how ketamine works and who might most benefit. This study explored how a personality trait called absorption may influence the benefits of a series of ketamine doses, paired with either music- or mindfulness-based support, for adults with severe depression. Trait absorption reflects an individual’s tendencies to become deeply immersed in sensory, imaginative, and emotional experiences. The results suggest that higher trait absorption is associated with greater benefits from ketamine, especially when administered with music. This may be because high-absorption individuals tend to have more significant ketamine experiences – indeed, the study found that higher trait absorption was associated with more mystical-like ketamine experiences. If confirmed, these results may help guide patient selection and the personalized use of mindfulness or music in ketamine therapy for depression. Garel et al. explore the influence of the personality trait absorption in the MUSIK trial which administered 181 doses of ketamine, with either music or mindfulness, for treatment-resistant depression. Higher absorption is associated with larger antidepressant effects, reduced suicidality, and more mystical experiences, especially with music-based support.

Authors

Institutions

Publication Details

Journal
Communications Medicine
Published
2026-11-14
DOI
https://doi.org/10.1038/s43856-026-01987-8
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Trait absorption association with ketamine’s benefits and drug-context interactions in treatment-resistant depression: exploratory results from the MUSIK randomized clinical trial

Soham Rej, David Erritzøe, Michael Lifshitz, Sara de la Salle et al.
Communications Medicine
Treatment of Major Depression
article

Trait absorption association with ketamine’s benefits and drug-context interactions in treatment-resistant depression: exploratory results from the MUSIK randomized clinical trial

Soham Rej, David Erritzøe, Michael Lifshitz, Sara de la Salle, Stéphane Richard‐Devantoy, Julien Thibault Lévesque, Nicolas Garel, Kyle T. Greenway, Juliette Vaugeois, Alyssa Bensoussan
article en

Abstract

Ketamine exerts rapid antidepressant effects in treatment-resistant depression (TRD) but therapeutic predictors remain elusive. The personality trait absorption – tendencies for immersive sensory, imaginative, and emotional experiences – influences responses to serotonergic psychedelics, like psilocybin, but has not been studied for ketamine. This study explores trait absorption’s influences on ketamine-therapy for TRD, including interactions with music- versus mindfulness-based support. This exploratory analysis draws on the MUSIK trial (NCT04701866), a multi-site, parallel, single-blind RCT at two Montreal hospitals, whose primary outcome examined hemodynamic effects of pairing ketamine with music. Thirty-two adults (aged 18-75 years) with severe TRD, receiving a structured psychedelic ketamine-therapy intervention, were randomized 1:1 to receive either music (n = 15) or matched non-music support (n = 17) during their six infusions (0.5 mg/kg over 40 min) over four weeks. Outcome assessors but not participants were blinded. Across 181 infusions, this exploratory outcome examined associations between baseline absorption and (1) changes in depression, anxiety, and suicidality; and (2) mystical/emotional experiences using linear correlations and multilevel models. Baseline trait absorption is associated (p ≤ .002) with pre-post improvements in depression (r = .721), anxiety (r = .546), and mean/peak Mystical Experience Questionnaire scores (r = .528-.637). In multilevel models, higher absorption is associated with steeper declines in depression and suicidality. Three-way interactions with timepoint and group suggest that music, versus matched non-music support, is associated with greater depression improvements in higher-absorption individuals (p <.001). Although confirmation in larger studies is required, this exploratory study suggests that trait absorption relates to ketamine’s benefits for TRD. Observed drug-context interactions highlight possible strategies for individuallytailoring ketamine-therapy. Low-dose ketamine can be very beneficial for severe depression even when other treatments have not helped. However, much remains unknown about how ketamine works and who might most benefit. This study explored how a personality trait called absorption may influence the benefits of a series of ketamine doses, paired with either music- or mindfulness-based support, for adults with severe depression. Trait absorption reflects an individual’s tendencies to become deeply immersed in sensory, imaginative, and emotional experiences. The results suggest that higher trait absorption is associated with greater benefits from ketamine, especially when administered with music. This may be because high-absorption individuals tend to have more significant ketamine experiences – indeed, the study found that higher trait absorption was associated with more mystical-like ketamine experiences. If confirmed, these results may help guide patient selection and the personalized use of mindfulness or music in ketamine therapy for depression. Garel et al. explore the influence of the personality trait absorption in the MUSIK trial which administered 181 doses of ketamine, with either music or mindfulness, for treatment-resistant depression. Higher absorption is associated with larger antidepressant effects, reduced suicidality, and more mystical experiences, especially with music-based support.

Communications Medicine
Queen's University Belfast (GB), Douglas Mental Health University Institute (CA), Jewish General Hospital (CA), NIHR Imperial Biomedical Research Centre (GB), Centre Hospitalier de l’Université de Montréal (CA), Lady Davis Institute for Medical Research (CA), Imperial College London (GB), McGill University (CA), Université de Montréal (CA)
Treatment of Major Depression
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon